Table 2.

Treatment-emergent adverse events reported by subjects

	Number of adverse events [number of subjects with adverse event]
MedDRA preferred term	Healthy subjects (10 µg exenatide) (n = 8)	Mild RI (10 µg exenatide) (n = 8)	Moderate RI (5 µg exenatide)* (n = 7)	ESRD (5 µg exenatide) (n = 8)
Vomiting NOS	9 [6]	6 [3]	0	10 [7]
Nausea	8 [8]	1 [1]	0	8 [7]
Headache†	7 [5]	2 [2]	0	6 [5]
Dizziness	1 [1]	3 [2]	0	0
Malaise	0	0	0	2 [2]
Tachycardia	1 [1]‡	0	0	1 [1]§
Other¶	2 [1]	5 [2]	0	1 [1]
Total	28 [8]	17 [5]	0	28 [7]

^*Two subjects in this group received 10 µg exenatide.

^†Five headache events were probably not related to exenatide.

^‡Medical Dictionary for Regulatory Activities (MedDRA) term: Tachycardia NOS (NOS = not otherwise specified).

^§MedDRA term: Sinus tachycardia.

^¶Dyspepsia, cold sweat and increased sweating (not related to hypoglycaemia), asthenia (twice), dry throat, abdominal pain upper, dyspnoea. Each reported by one subject.